| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10040472 | HBV | ENSG00000161267.12 | protein_coding | BDH1 | No | No | 622 | Q02338 |
| TVIS10051410 | HBV | ENSG00000161267.12 | protein_coding | BDH1 | No | No | 622 | Q02338 |
| TVIS10052013 | HBV | ENSG00000161267.12 | protein_coding | BDH1 | No | No | 622 | Q02338 |
| TVIS20057501 | HPV | ENSG00000161267.12 | protein_coding | BDH1 | No | No | 622 | Q02338 |
| TVIS44030172 | HTLV-1 | ENSG00000161267.12 | protein_coding | BDH1 | No | No | 622 | Q02338 |
| TVIS44019076 | HTLV-1 | ENSG00000161267.12 | protein_coding | BDH1 | No | No | 622 | Q02338 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | BDH1 |
|---|---|
| DrugBank ID | DB00157 |
| Drug Name | NADH |
| Target ID | BE0000175 |
| UniProt ID | Q02338 |
| Regulation Type | |
| PubMed IDs | 17139284; 17016423; 8533882; 2550053; 38961 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Tabata M, Totani M: A chemiluminescence-flow injection analysis of serum 3-hydroxybutyrate using a bioreactor consisting of 3-hydroxybutyrate dehydrogenase and NADH oxidase. Anal Biochem. 1995 Jul 20;229(1):133-8.@@Rudy B, Dubois H, Mink R, Trommer WE, McIntyre JO, Fleischer S: Coenzyme binding by 3-hydroxybutyrate dehydrogenase, a lipid-requiring enzyme: lecithin acts as an allosteric modulator to enhance the affinity for coenzyme. Biochemistry. 1989 Jun 27;28(13):5354-66.@@Smith CM, Plaut GW: Activities of NAD-specific and NADP-specific isocitrate dehydrogenases in rat-liver mitochondria. Studies with D-threo-alpha-methylisocitrate. Eur J Biochem. 1979 Jun;97(1):283-95. |
| Groups | Approved; Nutraceutical |
| Direct Classification | (5'->5')-dinucleotides |
| SMILES | NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C(N)N=CN=C23)[C@@H](O)[C@H]1O |
| Pathways | Ethylmalonic Encephalopathy; 3-Methylglutaconic Aciduria Type III; Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD Deficiency); Caffeine Metabolism; Fructose and Mannose Degradation; Isovaleric Aciduria; Lysine Degradation; Methylmalonic Aciduria Due to Cobalamin-Related Disorders; Glycerol Phosphate Shuttle; Zellweger Syndrome; Propionic Acidemia; Glycolysis; Xanthine Dehydrogenase Deficiency (Xanthinuria); S-Adenosylhomocysteine (SAH) Hydrolase Deficiency; Tryptophan Metabolism; Glutaric Aciduria Type I; 3-Methylcrotonyl-CoA Carboxylase Deficiency Type I; Glycine N-Methyltransferase Deficiency; Dimethylglycine Dehydrogenase Deficiency; Androgen and Estrogen Metabolism; Nucleotide Sugars Metabolism; 3-Methylglutaconic Aciduria Type IV; Dihydropyrimidine Dehydrogenase Deficiency (DHPD); Malate-Aspartate Shuttle; Folate Metabolism; Valine, Leucine, and Isoleucine Degradation; Maple Syrup Urine Disease; Glycerol Kinase Deficiency; Adenylosuccinate Lyase Deficiency; Cysteine Metabolism |
| PharmGKB | PA164755085 |
| ChEMBL | CHEMBL1234616 |
